15739208

Source:http://linkedlifedata.com/resource/pubmed/id/15739208

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0034897, umls-concept:C0036525, umls-concept:C0282460, umls-concept:C1176309, umls-concept:C1261473, umls-concept:C1522484
pubmed:issue	7
pubmed:dateCreated	2005-3-24
pubmed:abstractText	Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/N01-CM17105, http://linkedlifedata.com/resource/pubmed/grant/P01-CA47179
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines, http://linkedlifedata.com/resource/pubmed/chemical/bortezomib
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0008-543X
pubmed:author	pubmed-author:AntonescuCristina RCR, pubmed-author:KraftAndrew SAS, pubmed-author:MakiRobert GRG, pubmed-author:ScheuKellyK, pubmed-author:SchwartzGary KGK, pubmed-author:WadlerScottS, pubmed-author:WrightJohn JJJ, pubmed-author:YamadaJenniferJ
pubmed:copyrightInfo	Copyright 2005 American Cancer Society.
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	103
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1431-8
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:15739208-Adult, pubmed-meshheading:15739208-Aged, pubmed-meshheading:15739208-Antineoplastic Agents, pubmed-meshheading:15739208-Bone Neoplasms, pubmed-meshheading:15739208-Boronic Acids, pubmed-meshheading:15739208-Drug Administration Schedule, pubmed-meshheading:15739208-Fatigue, pubmed-meshheading:15739208-Female, pubmed-meshheading:15739208-Humans, pubmed-meshheading:15739208-Male, pubmed-meshheading:15739208-Middle Aged, pubmed-meshheading:15739208-Neoplasm Metastasis, pubmed-meshheading:15739208-Neoplasm Recurrence, Local, pubmed-meshheading:15739208-Nervous System Diseases, pubmed-meshheading:15739208-Proteasome Endopeptidase Complex, pubmed-meshheading:15739208-Pyrazines, pubmed-meshheading:15739208-Sarcoma, pubmed-meshheading:15739208-Soft Tissue Neoplasms, pubmed-meshheading:15739208-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
pubmed:affiliation	Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6007, USA. makir@mskcc.org
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Multicenter Study